# Cabergoline and Hydroxyethyl Starch in Ovarian Hyperstimulation Syndrome Prevention

> **NCT01530490** · EARLY_PHASE1 · COMPLETED · sponsor: **Hospital de Cruces** · enrollment: 80 (actual)

## Conditions studied

- Complications Associated With Artificial Fertilization
- Disorder of Endocrine Ovary

## Interventions

- **DRUG:** Cabergoline and Hydroxyethyl Starch
- **DRUG:** Hydroxyethyl Starch

## Key facts

- **NCT ID:** NCT01530490
- **Lead sponsor:** Hospital de Cruces
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2008-08
- **Final completion:** 2010-09
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2012-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01530490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01530490, "Cabergoline and Hydroxyethyl Starch in Ovarian Hyperstimulation Syndrome Prevention". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01530490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*